Beijing Peking University Weiming Bioengineering Group Co., Ltd. (hereinafter referred to as Peking University Weiming) is one of the four major industrial groups in Peking University, mainly engaged in bioengineering and pharmaceuticals, including the technical research, development, industrialization and commercialization of genetic engineering pharmaceuticals, natural medicines, chemical medicines, biochemical drugs, vaccines, diagnostic reagents, agricultural bioengineering and phase III health care products. It is the largest bioengineering enterprise group in China and has great international competition potential.

Peking University was founded by Dr. Chen and Dr. Pan Aihua in1June+1September/992. After ten years of pioneering work, it has developed from a small enterprise with a liquidity of only 400,000 yuan to the largest bioengineering group company in China. At present, Peking University has a shareholding in 10 enterprises, including Shandong Kexing Biological Products Co., Ltd., Beijing Kexing Biological Products Co., Ltd., Shenzhen Kexing Biological Engineering Co., Ltd., Xiamen Beidazhi Road Biological Engineering Co., Ltd. and Shenzhen Peking University High-tech Co., Ltd. (listed on Shenzhen Stock Exchange, stock code: 000004), and owns more than 20 kinds of biological drugs, including 3 kinds of national first-class new drugs. Peking university has the top five sales of recombinant human erythropoietin (iprodine &; Reg Ebosie Nuo company. Reg), recombinant human granulocyte colony stimulating factor injection (Baxter &; Reg, white-c & Reg), recombinant human insulin injection (sulindan &; Reg, Su Meilin & ampreg), recombinant human growth hormone (Gao Sai Road &; RegSigrow & ampreg), recombinant human interferon α (Siroquine &; reg、SINOGEN & ampreg); In addition, it also has an inactivated hepatitis A vaccine with independent intellectual property rights (Hailaifu &; Reg Healthy Living & ampreg) and the world's first nerve growth factor drug (Enjingfu &; Reg Norrback & ampreg) and other internationally competitive products. Peking University has 1 1 production lines that meet international GMP standards. After several years of development, Peking University has established R&D centers in Beijing, Shenzhen and Xiamen with a total area of nearly 30,000 square meters, superior conditions and beautiful environment. With its own research and development strength, we have developed world-class products such as nerve growth factor, inactivated hepatitis A vaccine and genetically engineered insulin, and more than ten projects with independent intellectual property rights and good market prospects are under development. Peking University Weiming has a unique resource advantage in the research and development and production capacity of biopharmaceuticals, especially genetic engineering drugs. Starting from 1999, three major bioengineering industrialization bases, namely, Beijing Peking University Bio-City, Shenzhen Peking University Bio-Valley and Xiamen Peking University Bio-Park, were initially established, which laid a solid foundation for the further development of Peking University.